Literature DB >> 24982352

PROX1 expression in gastric cancer: from hypothesis to evidence.

Oana Taban1, Anca Maria Cimpean2, Marius Raica1, Sorin Olariu3.   

Abstract

BACKGROUND: PROX1 is involved in cancer development and progression as both a tumor suppressor and oncogene. Immunohistochemical (IHC) PROX1 nuclear expression is a widely accepted pattern. Scattered data reported PROX1 IHC cytoplasmic expression in different tumors, including gastric cancer but it is not clear if this holds true.
MATERIALS AND METHODS: Evaluation of the cytoplasmic expression of PROX1 in normal gastric mucosa and gastric cancer was performed by IHC followed by RNAscope, an in situ hybridization-based method for detecting PROX1 mRNA amplification on paraffin-embedded samples and to evaluate its clinical impact.
RESULTS: Twenty five out of 48 cases of gastric cancer showed PROX1 nuclear and cytoplasmic immunohistochemical expression. Twelve out of these 20 cases positive for PROX1 on IHC (54.5%) had PROX1 mRNA gene amplification. The overlapping of PROX1 cytoplasmic expression assessed by immunohistochemistry and cytoplasmic RNAscope amplification was statistically significant (p=0.031). PROX1 mRNA gene amplification correlated with tumor grade (p=0.05) and regional lymph node metastasis as well (p=0.033). No significant correlation was obtained between PROX1 and histopathology, tumor size or distal metastasis.
CONCLUSION: A significant correlation was found between IHC and RNAscope PROX1 expression in the cytoplasm of normal and gastric cancer cells. This strongly supports its validation as a true expression on immunohistochemistry. A strong correlation between PROX1 mRNA amplification and regional lymph node metastasis supports its implications in cancer spreading and metastasis and sustains its utility, not only as a lymphatic marker, but also as a potential tumor marker in various tumor types, including gastric cancer. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  PROX1; RNAscope; gastric cancer; immunohistochemistry

Mesh:

Substances:

Year:  2014        PMID: 24982352

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.

Authors:  Kang-Jin Park; Sung-Bum Cho; Young-Lan Park; Nuri Kim; Sun-Young Park; Dae-Seong Myung; Wan-Sik Lee; Sun-Seog Kweon; Young-Eun Joo
Journal:  Gastric Cancer       Date:  2016-01-12       Impact factor: 7.370

2.  Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells.

Authors:  Dongwon Choi; Swapnika Ramu; Eunkyung Park; Eunson Jung; Sara Yang; Wonhyeuk Jung; Inho Choi; Sunju Lee; Kyu Eui Kim; Young Jin Seong; Mingu Hong; George Daghlian; Daniel Kim; Eugene Shin; Jung In Seo; Vicken Khatchadourian; Mengchen Zou; Wei Li; Roger De Filippo; Paul Kokorowski; Andy Chang; Steve Kim; Ana Bertoni; Tania Weber Furlanetto; Sung Shin; Meng Li; Yibu Chen; Alex Wong; Chester Koh; Jan Geliebter; Young-Kwon Hong
Journal:  Cancer Res       Date:  2015-11-25       Impact factor: 12.701

3.  Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model.

Authors:  Anca Maria Cimpean; Dusan Lalošević; Vesna Lalošević; Pavle Banović; Marius Raica; Ovidiu Alexandru Mederle
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

4.  PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.

Authors:  Kapo Saukkonen; Jaana Hagström; Harri Mustonen; Anne Juuti; Stig Nordling; Pauliina Kallio; Kari Alitalo; Hanna Seppänen; Caj Haglund
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

5.  Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells.

Authors:  Magdalena Rudzińska; Małgorzata Grzanka; Anna Stachurska; Michał Mikula; Katarzyna Paczkowska; Tomasz Stępień; Agnieszka Paziewska; Jerzy Ostrowski; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2019-05-05       Impact factor: 5.923

6.  Clinico-pathological and prognostic implications of Srx, Nrf2, and PROX1 expression in gastric cancer and adjacent non-neoplastic mucosa - an immunohistochemical study.

Authors:  Abeer M Hafez; Ola A Harb; Ahmed Z Alattar; Nabila Hefzi; Rham Z Ahmed; Shady E Shaker; Amr Ibrahim; Ahmed K El-Taher
Journal:  Contemp Oncol (Pozn)       Date:  2021-01-04

Review 7.  The Role of PROX1 in Neoplasia: A Key Player Often Overlooked.

Authors:  Evangelia Ntikoudi; Alexandros Pergaris; Stylianos Kykalos; Ekaterini Politi; Stamatios Theocharis
Journal:  Diagnostics (Basel)       Date:  2022-07-04

8.  High PROX1 expression in gastric cancer predicts better survival.

Authors:  Alli Laitinen; Camilla Böckelman; Jaana Hagström; Arto Kokkola; Pauliina Kallio; Caj Haglund
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.